Abstract
Advanced gastrointestinal cancer patients with weight loss and an acute-phase response (n = 15) were given megestrol acetate (480 mg day(-1)) and ibuprofen (1200 mg day(-1)) for 6 weeks. Overall, there was an increase in body weight (P = 0.01) and a reduction in C-reactive protein concentrations (P = 0.02), with no change in total body water (P = 0.24) over this period. This regimen may be an effective non-toxic treatment for cancer cachexia and is worthy of further study.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McMillan, D., O'Gorman, P., Fearon, K. et al. A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients. Br J Cancer 76, 788–790 (1997). https://doi.org/10.1038/bjc.1997.463
Issue Date:
DOI: https://doi.org/10.1038/bjc.1997.463
This article is cited by
-
Cancer cachexia: impact, mechanisms and emerging treatments
Journal of Cachexia, Sarcopenia and Muscle (2013)
-
Serum leptin concentration and advanced gastrointestinal cancers: a case controlled study
BMC Cancer (2004)
-
Cachexia in cancer patients
Nature Reviews Cancer (2002)
-
A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss
British Journal of Cancer (1999)
-
The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer
British Journal of Cancer (1999)
